Common use of ZENECA Diligence Obligation Clause in Contracts

ZENECA Diligence Obligation. (a) ZENECA will use commercially reasonable efforts to develop a Development Candidate as expeditiously as possible consistent with ZENECA's own practices for drugs of similar commercial potential and for all indications for which ZENECA reasonably determines the Development Candidate is likely to be commercially attractive. If ZENECA determines that it will not develop a Development Candidate for such commercially attractive indication outside of the initial therapeutic focus of the Target as determined by the Joint Research Committee, taking into account ZENECA's overall development plan for the Development Candidate for all indications, ZENECA will reasonably consider development and commercialization of the Development Candidate by ISIS or a Third Party in any indication ZENECA is not pursuing. Such consideration by ZENECA will be intended to maximize the commercial value of the Development Candidate to ZENECA and ISIS without jeopardizing the development or commercialization of the Development Candidate by ZENECA in the indication ZENECA is pursuing. Determination by ZENECA not to permit such commercialization on the grounds that such development could jeopardize the development or commercialization of the Development Candidate shall be deemed to be reasonable. * CONFIDENTIAL TREATMENT REQUESTED